Phase 3 clinical trial results (TRANSCEND-T2D-1) published in The Lancet report that retatrutide, an investigational once-weekly injection for diabetes management, can significantly improve blood sugar levels and lead to substantial

Whether it’s been about weight, blood sugar, PCOS, food noise, or something else entirely, we want to hear.View Entire Post ›

(MedPage Today) — Variable weight-loss and cardiovascular benefits were seen with GLP-1 drugs in a systematic review and network meta-analysis, but effects on quality of life were less clear.

Friday, July 10 – (MedPage Today) — Analysis of hundreds of thousands of patient records showed differing risks for autoimmune disorders for new users of the more recent types of

Friday, July 10 – The share of U.S. adults taking GLP-1 medications to lose weight has reached a record 11%.

Friday, July 10 – Obesity and dietitian societies have joined forces to issue a new consensus statement on recommendations surrounding the use of obesity drugs for weight loss treatment. The

Friday, July 10 – Medicare prescriptions for Wegovy increased sharply after the program started covering the anti-obesity medication to prevent heart problems, but just a fraction of beneficiaries likely eligible

Friday, July 10 – (MedPage Today) — Diabetes patients with hepatocellular carcinoma (HCC) experienced longer time to HCC recurrence and longer survival when they initiated a GLP-1 agonist rather than

Thursday, July 9 – Poison control calls involving semaglutide (Ozempic and Wegovy) soared after the drug was approved for weight management, with researchers linking the increase to accidental dosing mistakes

Thursday, July 9 – (MedPage Today) — Americans’ use of GLP-1 injectables for weight loss reached a record high, nearly quadrupling since 2024, according to a national Gallup poll.

Thursday, July 9 – The new Medicare GLP-1 Bridge program offers broader, more affordable access to weight loss drugs to address the growing obesity crisis. But there’s a catch when

Thursday, July 9 – Getting a GLP-1 prescription online can be quick and convenient, but new research suggests it may come with surprisingly little medical oversight. The findings are published

Thursday, July 9 – New data on Hengrui Pharma and Kailera Therapeutics’ investigational oral GLP-1 have validated the late-stage weight loss asset and paved the road for a regulatory submission

Wednesday, July 8 – Survodutide weight-loss drug may reduce harmful fat while preserving muscle

Wednesday, July 8 – AstraZeneca’s new oral GLP-1 pill showed promising results for weight loss and blood sugar in a phase 2 trial. Guido Mieth/Getty Images

A new GLP-1 oral

Wednesday, July 8 – A new once-daily weight-loss pill called orforglipron delivered better weight loss and blood sugar improvements for people with type 2 diabetes than the leading oral semaglutide

Tuesday, July 7 – Federal regulators have agreed to review a Swiss pharmaceutical company’s applications for two cheaper generic versions of Zepbound and Mounjaro. MK Photo/Alamy Stock Photo

Federal regulators

Tuesday, July 7 – (MedPage Today) — Two-thirds of online GLP-1 receptor agonist sellers did not require speaking with a clinician ahead of a prescription, a secret shopper study revealed.<br

Tuesday, July 7 – (MedPage Today) — At the American Diabetes Association annual meeting, results from the ACHIEVE-5 trial showed that adding oral orforglipron (Foundayo) to basal insulin significantly improved

Tuesday, July 7 – A new secret-shopper study found that GLP-1 prescriptions from telehealth sites aren’t often backed by appropriate clinical care.

Tuesday, July 7 – Thousands of people begin receiving their first deliveries of once-a-day medication made by Novo Nordisk A once-a-day Wegovy weight-loss pill has gone on sale at high

Tuesday, July 7 – Option offers once‑daily semaglutide tablets for adults living with obesity

Monday, July 6 – “Obesity will become a disease of poverty.”View Entire Post ›

Monday, July 6 – The once-a-day pill, from the makers of the Wegovy weight-loss jab, can now be bought privately in UK pharmacies.

Saturday, July 4 – A new biweekly GLP-1 injection has been shown to significantly reduce blood sugar in a clinical trial. Image Credit: Hannes P Albert/picture alliance via Getty Images

Saturday, July 4 – (MedPage Today) — Popular — and expensive — GLP-1 agonists for weight loss just got a lot cheaper for many older Americans.
Starting this week,

Friday, July 3 – Semaglutide may lower risk of serious complications in high-risk diabetes

Saturday, July 4 – On June 16, 2026, the US Food and Drug Administration (FDA) issued 25 warning letters to various telehealth companies alleging that their websites contained false or

Friday, July 3 – For decades, it’s been against the law for Medicare to pay for weight-loss medication. But that changed on July 1, with the launch of a new

WEDNESDAY, July 1, 2026 — Glucagon-like peptide-1 receptor agonist (GLP-1 RA) exposures reported to U.S. poison centers increased following 2021 U.S. Food and Drug Administration (FDA) approval for weight loss,

WEDNESDAY, July 1, 2026 — Glucagon-like peptide-1 receptor agonist (GLP-1 RA) exposures reported to U.S. poison centers increased following 2021 U.S. Food and Drug Administration (FDA) approval for weight loss,

Thursday, July 2 – Individuals with atrial fibrillation (Afib), or irregular heart rhythm, are at increased risk of stroke, chronic kidney disease and heart failure. These risks are significantly exacerbated

Thursday, July 2 – (MedPage Today) — Patients with hidradenitis suppurative (HS) and a history of GLP-1 receptor agonist use for diabetes or obesity had significantly lower rates of multiple

Thursday, July 2 – A form of fibre that boosts the release of the hunger-reducing hormone GLP-1 has been approved as safe by a European regulator, and could be added

Thursday, July 2 – Anthropic will begin developing drugs, BridgeBio pockets a billion, and more biotech news from The Readout

Thursday, July 2 – The federal government has launched a new program to make GLP-1 weight loss drugs more affordable for older Americans

Thursday, July 2 – Welcome to the “Temu experience of telehealth,” where everyone from Grindr to MAGA influencers can open a virtual clinic selling weight loss drugs and more.

Thursday, July 2 – (MedPage Today) — Incretin-based therapies after bariatric surgery were associated with clinically meaningful augmented weight loss in a dose- and timing-dependent manner, according to U.S. cohort

Wednesday, July 1 – Corxel Pharmaceuticals Ltd.’s oral small-molecule GLP-1 receptor agonist, CX-11, met the primary endpoints in a phase II trial evaluating the candidate in obese and overweight patients

Wednesday, July 1 – A new pilot program will allow Medicare Part D beneficiaries to access popular weight loss drugs, including Wegovy, Zepbound and Foundayo, at a significantly reduced price

Tuesday, June 30 – A growing body of evidence shows that GLP-1 drugs benefit cardiovascular health. Image Credit: Healthline/Munro/Getty Images

GLP-1 medications like Ozempic and Wegovy help protect heart health,

Tuesday, June 30 – Scientists at The Wistar Institute have shown that a single injection of a small, circular piece of genetic instruction can produce weight loss and blood glucose

Tuesday, June 30 – (MedPage Today) — At the American Diabetes Association annual meeting, 2-year results from the SUPPRESS-EARLY trial showed that initiating tirzepatide (Mounjaro, Zepbound) early in the course

Tuesday, June 30 – Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as Ozempic or Wegovy, have revolutionized type 2 diabetes and weight-loss management, but they have also led to some

Saturday, June 27 – GLP-1 drugs can provide benefits that may boost an athlete’s performance, but do these medications give them the competitive edge? Getty Images/The Good Brigade

Debates are

Saturday, June 27 – (MedPage Today) — Use of GLP-1 receptor agonists was associated with a higher risk of smell and taste disturbances among adults with type 2 diabetes, an

Saturday, June 27 – “‘Mommy has to take shots to conform to what other people think will look better.'”View Entire Post ›

Saturday, June 27 – A report about unusual access to an experimental obesity drug has raised interest in the condition pulmonary hypertension.

Friday, June 26 – Some GLP-1 users report changes in their taste and smell, according to a new study. Tatsiana Volkava/Getty Images

Researchers report that GLP-1 drugs used to treat

Friday, June 26 – As the use of GLP-1 medications for weight loss surges, so do calls to U.S. poison control centers, according to a new study.

Friday, June 26 – (MedPage Today) — In patients with inflammatory bowel disease (IBD), the use of GLP-1 receptor agonists was linked to a lower risk of colorectal cancer (CRC),

Friday, June 26 – As people age, they often develop chronic conditions, many of which need to be managed with multiple prescription medications. While medications are important for disease management,

THURSDAY, June 25, 2026 — As the use of GLP-1 medications for weight loss surges, so do calls to U.S. poison control centers, according to a new study.
A

Friday, June 26 – A new strategy for delivering GLP-1 drugs to patients with obesity or who were overweight resulted in up to a 12% reduction in body weight after

Thursday, June 25 – An estimated 14 million Medicare Part D recipients could obtain Wegovy, Foundayo, and Zepbound for $50 per month. Johner Images/Getty Images

Federal officials announced the launch

Thursday, June 25 – People are getting more care and using lots of GLP-1 drugs, fueling a sharp increase in health care spending.

Drug buyers want a New York federal judge to preserve proposed class claims accusing Novo Nordisk of paying Teva to delay generic competition with its Victoza GLP-1 drug, arguing that

Thursday, June 25 – (MedPage Today) — Use and misuse of GLP-1 receptor agonists were common in people with eating disorders, interim results of an ongoing cross-sectional study suggested.

Eli Lilly and Co. posted $19.8 billion in first-quarter 2026 revenue, driven by tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for obesity. The Indianapolis-based drugmaker is channeling

Corxel Pharmaceuticals Ltd.’s oral small-molecule GLP-1 receptor agonist, CX-11, met the primary endpoints in a phase II trial evaluating the candidate in obese and overweight patients in the U.S., according

Wednesday, June 24 – Giving an individual special access to an experimental obesity drug is highly unusual.

Wednesday, June 24 – The “triple-G” weight loss drug, Pfizer’s lung cancer trial results, and more biotech news from The Readout

Wednesday, June 24 – Eli Lilly’s weight-loss franchise—including the tirzepatide products Mounjaro and Zepbound, and the weight-loss pill Foundayo—is projected to account for nearly half of the total sales of

Tuesday, June 23 – Wegovy, Zepbound named first choice for obesity treatment in new guidelines

Tuesday, June 23 – Researchers say that GLP-1 drugs containing tirzepatide (Zepbound, Mounjaro) may lead to greater weight loss. Image Credit: Tatsiana Volkava/Getty Images

A meta-analysis found that one type

Tuesday, June 23 – (MedPage Today) — At the American Diabetes Association annual meeting, updated phase II data from the VESPER program showed that patients who achieved weight loss with

Tuesday, June 23 – For many people, the thought of a tasty burger or a cold pint of beer conjures a vivid mental image and drives behavior. This link between

Monday. June 22 – The obesity treatment landscape is changing fast, with GLP-1 drugs opening the door to more effective care than ever before. Experts now envision a future where

Saturday, June 20 – GLP-1s may help reduce impulsivity, alcohol intake, and violent behaviors in adults. Image Credit: munro/gettyimages

A recent study found that GLP-1 medications like Ozempic and Wegovy

Saturday, June 20 – GLP-1 weight loss drugs like Ozempic are linked to cosmetic concerns, including sagging earlobes, deflated breasts and flatter buttocks, surgeons say.

FRIDAY, June 19, 2026 — Ozempic doesn’t only help people lose weight, but might also protect against broken bones, a new study says.
People with type 2 diabetes treated

Friday, June 19 – GLP-1 drugs show early promise for improving fertility in males and females

Friday, June 19 – Mayim Bialik recently shared the “nightmare” experience she had after using a GLP-1 drug. Image Credit: Laurent Koffel/Getty Images

Actor Mayim Bialik has shared her “nightmare”

Friday, June 19 – Setting a weight loss goal may yield greater success with GLP-1 drugs like Zepbound. Image Credit: Crispin la valiente/GettyImages

A recent study found that people who

Friday, June 19 – What’s next for GLP-1 weight loss drugs? Alex Hogan explores on the new episode of STATus Report. Watch now.

Friday, June 19 – (MedPage Today) — The FDA cleared Wave Neuroscience’s biomarker-guided neuromodulation system (MeRT) to treat post-traumatic stress disorder (PTSD), the company announced.
Gastrointestinal interoception was disrupted

WEDNESDAY, June 17, 2026 — Adults with obesity initiating glucagon-like peptide-1 receptor agonist (GLP-1RA) medications have a significant decrease in their physical activity, according to a study presented at ENDO

WEDNESDAY, June 17, 2026 — More than half of adults with type 2 diabetes mellitus (T2DM) who discontinue glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reinitiate within one year, according to

Wednesday, June 17 – Using GLP-1s may increase your risk of heat-related illnesses. Image Credit: Nora Carol Photography/Getty Images

GLP-1 medications may increase heat-related risks by suppressing thirst and reducing

A Rutgers study suggests GLP-1 drugs such as Ozempic and Wegovy may weaken the link between impulsive tendencies and violent behavior. The surprising finding hints that these medications could affect

Wednesday, June 17 – New research finds GLP-1 users significantly reduced physical activity, with daily steps and exercise declining after starting a weight loss medication.

WEDNESDAY, June 17, 2026 — People with an autoimmune disease and obesity might lower their risk of dangerous blood clots and death by taking Ozempic or Zepbound, a new study

Wednesday, June 17 – The rapid rise of GLP-1 medications such as semaglutide and tirzepatide has transformed obesity treatment. Still, experts say medications alone are not enough to address one

Wednesday, June 17 – Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have become popular for weight loss, but results vary from person to person and from drug to drug. Venky Soundararajan and

Wednesday, June 17 – Eli Lilly has agreed to drop a lawsuit accusing two Washington clinics of ripping off its trademarks for the weight loss drugs Mounjaro and Zepbound, according

Wednesday, June 17 – (MedPage Today) — A massive wave of new prescriptions for GLP-1 receptor agonists is expected following the July launch of a Medicare pilot program that offers

TUESDAY, June 16, 2026 — Orforglipron is beneficial for blood glucose control in individuals with type 2 diabetes using metformin or taking insulin glargine, according to two studies published online

Monday, June 15 – Eli Lilly’s recent GLP-2 deal with Hanmi Pharm is another step in the drugmaker’s quest to grow its GLP franchise beyond weight loss and deepen its

Monday, June 15 – Many people prescribed GLP-1 drugs for type 2 diabetes (such as Victoza, Ozempic, or tirzepatide) stop taking them, but a surprising number later return to treatment.

Monday, June 15 – A large real-world study suggests semaglutide (Ozempic, Wegovy, Rybelsus) may offer an unexpected bonus for people with type 2 diabetes: stronger protection against bone fractures while

TUESDAY, June 16, 2026 — Folks losing weight on Ozempic or Zepbound tend to start slacking off when it comes to exercise, a new study says.
People’s daily step

Tuesday, June 16 – One of the largest real-world studies of people taking GLP-1 medications found women, those without pre-existing conditions such as type 2 diabetes and high blood pressure,

Tuesday, June 16 – Tirzepatide doesn’t just help people lose weight; it also activates brown adipose tissue, representing a major milestone in obesity research, according to a study presented at

Tuesday, June 16 – (MedPage Today) — CHICAGO — The GLP-1 receptor agonist semaglutide (Ozempic, Wegovy) was associated with a 15% lower risk for fractures in adults with type 2

MONDAY, June 15, 2026 — Selective targeting of myostatin by apitegromab preserves lean mass when combined with tirzepatide, according to a study published online June 8 in Nature Medicine.

MONDAY, June 15, 2026 — Among patients with preexisting hypertension taking antihypertensive medications, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with an increase in hypotensive-related events, according to

Monday, June 15 – GLP-1 medications are marketed to help you lose weight, but one may be better at it than the rest, according to a new meta-analysis from the

Monday, June 15 – GLP-1s do not harm male hormones or fertility after long-term use, according to a study being presented Monday at ENDO 2026, the Endocrine Society’s annual meeting